Front-line Therapy

A molecule that targets a cell’s mechanism for breaking down unneeded proteins can kill multiple myeloma cancer cells that have become resistant to bortezomib and other myeloma drugs, researchers at Dana-Farber Cancer Institute have found.

Lead investigator Dharminder Chauhan, PhD, described the research in an interview with Value-Based Care in Myeloma. The results of the study were recently published (Chauhan D, et al. Cancer Cell. 2012;22:345-358).

High-dose (HD) chemotherapy followed by auto­logous stem cell transplant (ASCT) has dramatically improved the care of patients with multiple myeloma (MM).

The increased risk of reactivation of the varicella zoster virus (VZV) infection (a type of herpes zoster) observed in previous studies of bortezomib-based therapy was completely abrogated in patients with multiple myeloma who received prophylaxis with acyclovir, in a series of patients treated at Roswell Park Cancer Institute, Buffalo, NY.  

Despite advances in the treatment of multiple myeloma, survival time is short for many newly diagnosed patients, often because of treatment complications.

Results 1 - 6 of 6
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology